论文部分内容阅读
作者观察了两组急性粒细胞白血病(AML)缓解后接受不同治疗的结果。第一组15例,单用免疫治疗:卡介苗加照射过的同种AML细胞注射;第二组17例,免疫治疗(同上)加化疗(所用药物为诱导缓解时用药)。两组中数缓解期都为245天,第一组中数生存期476天,第二组564天,无明显差异。对于化疗药物为什么不能延长缓解期,作者认为不能归因于抗药性,因为一旦复发后,两组病人用化疗药物后第二次缓解率相同。而可能是由于白血病细
The authors observed the results of different treatments after remission of acute myelogenous leukemia (AML) in both groups. In the first group, 15 patients were treated with immunotherapy alone: BCG plus irradiated AML cells of the same kind; in the second group, 17 patients were treated with immunotherapy (same as above) plus chemotherapy (the drug was used for induction of remission). The median time of remission in both groups was 245 days. The median survival time was 476 days in the first group and 564 days in the second group. There was no significant difference. The reason why the chemotherapeutic drugs do not extend the remission period is considered by the authors not to be attributed to drug resistance, because once the relapse occurs, the second remission rate is the same for the two groups of patients after the use of chemotherapy drugs. And it may be due to leukemia